{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["61(4)"],"submitter":["Onal H"],"pubmed_abstract":["<h4>Aim</h4>To determine whether convalescent angiotensin (1-7) peptide replacement therapy with plasma (peptide plasma) transfusion can be beneficial in the treatment of critically ill patients with severe coronavirus 2 (SARS-CoV-2) infection.<h4>Study design</h4>Case series of 9 critically ill patients with laboratory-confirmed COVID-19 who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment. Peptide plasma: Plasma with angiotensin (1-7) content 8-10 times higher than healthy plasma donors was obtained from suitable donors. Peptide plasma transfusion was applied to 9 patients whose clinical status and/or laboratory profile deteriorated and who needed intensive care for 2 days.<h4>Results</h4>In our COVID-19 case"],"journal":["Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis"],"pagination":["103418"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8917875"],"repository":["biostudies-literature"],"pubmed_title":["Angiotensin (1-7) peptide replacement therapy with plasma transfusion in COVID-19."],"pmcid":["PMC8917875"],"pubmed_authors":["Kalkan A","Arslan B","Onal H","Semerci SY","Ergun NU","Topuz S","Kocatas A","Ugurel OM","Topuzogullari M","Suner N","Yoldemir SA"],"additional_accession":[]},"is_claimable":false,"name":"Angiotensin (1-7) peptide replacement therapy with plasma transfusion in COVID-19.","description":"<h4>Aim</h4>To determine whether convalescent angiotensin (1-7) peptide replacement therapy with plasma (peptide plasma) transfusion can be beneficial in the treatment of critically ill patients with severe coronavirus 2 (SARS-CoV-2) infection.<h4>Study design</h4>Case series of 9 critically ill patients with laboratory-confirmed COVID-19 who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment. Peptide plasma: Plasma with angiotensin (1-7) content 8-10 times higher than healthy plasma donors was obtained from suitable donors. Peptide plasma transfusion was applied to 9 patients whose clinical status and/or laboratory profile deteriorated and who needed intensive care for 2 days.<h4>Results</h4>In our COVID-19 case","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-19T22:56:52.453Z","creation":"2024-11-19T21:53:54.647Z"},"accession":"S-EPMC8917875","cross_references":{"pubmed":["35305923"],"doi":["10.1016/j.transci.2022.103418"]}}